Study S002792

A Phase 2, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of UBT251 Injection in Adult Patients With Metabolic Dysfunction-associated Steatohepatitis (MASH)

ClinicalTrials.gov record

Registration

Registration: NCT07145151
Acronym: MASH
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: TRIPLE
Status: RECRUITING
Enrollment: 156
Start: 2025-09-30
Primary completion: 2027-06-04
Lead sponsor: The United Bio-Technology (Hengqin) Co., Ltd.
Conditions: Metabolic Dysfunction-associated Steatohepatitis (MASH)
Interventions: DRUG:UBT251; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: OTHER:Approved No.:2023LP01795

Registered primary outcomes

Percentage of Participants With MASH resolution With no Worsening of Fibrosis on Liver Histology [Baseline, Week 48]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.